Last reviewed · How we verify

NCT00365157

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Active, enrolled Phase 1, PHASE2 Last updated 11 July 2025
What this trial tests

Phase 1, PHASE2 trial testing Eribulin Mesylate in Advanced Urothelial Carcinoma in 132 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
23 October 2006
Primary endpoint
9 July 2025
9 July 2026

Quick facts

Lead sponsorNational Cancer Institute (NCI)
PhasePhase 1, PHASE2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment132
Start date23 October 2006
Primary completion9 July 2025
Estimated completion9 July 2026
Sites26 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, any sex, with Advanced Urothelial Carcinoma or Locally Advanced Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body (metastatic)and kidney dysfunction. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective.
    Ong MS, Deng S, Halim CE, Cai W, et al · · 2020 · cited 90× · PMID 31963677 · DOI 10.3390/cancers12010238
  2. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma.
    Mollica V, Rizzo A, Montironi R, Cheng L, et al · · 2020 · cited 75× · PMID 32498352 · DOI 10.3390/cancers12061449
  3. Eribulin in Cancer Treatment.
    Swami U, Shah U, Goel S. · · 2015 · cited 46× · PMID 26262627 · DOI 10.3390/md13085016
  4. Targeted therapies in urothelial carcinoma.
    Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. · · 2014 · cited 37× · PMID 24685646 · DOI 10.1097/cco.0000000000000064
  5. Current therapeutic strategies for invasive and metastatic bladder cancer.
    Vishnu P, Mathew J, Tan WW. · · 2011 · cited 35× · PMID 21792316 · DOI 10.2147/ott.s22875
  6. Eribulin mesylate in the treatment of metastatic breast cancer.
    Jain S, Cigler T. · · 2012 · cited 27× · PMID 22291464 · DOI 10.2147/btt.s19811
  7. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
    Kurtoglu M, Davarpanah NN, Qin R, Powles T, et al · · 2015 · cited 15× · PMID 25862322 · DOI 10.1016/j.clgc.2015.02.009
  8. Systemic therapy in bladder cancer.
    Pinto IG. · · 2017 · cited 9× · PMID 28469299 · DOI 10.4103/iju.iju_294_16

Verify or expand the search:

Other trials of Eribulin Mesylate

Trials testing the same drug.

Other recruiting trials for Advanced Urothelial Carcinoma

Currently open trials in the same condition.

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00365157.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing